AU4741697A - Compositions and methods for the prevention and diagnosis of human granulocytic ehrlichiosis - Google Patents

Compositions and methods for the prevention and diagnosis of human granulocytic ehrlichiosis

Info

Publication number
AU4741697A
AU4741697A AU47416/97A AU4741697A AU4741697A AU 4741697 A AU4741697 A AU 4741697A AU 47416/97 A AU47416/97 A AU 47416/97A AU 4741697 A AU4741697 A AU 4741697A AU 4741697 A AU4741697 A AU 4741697A
Authority
AU
Australia
Prior art keywords
aohge
polypeptide
polypeptides
kda
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU47416/97A
Other languages
English (en)
Inventor
Stephen W Barthold
Erol Fikrig
Jacob Ijdo
Wei Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of AU4741697A publication Critical patent/AU4741697A/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/29Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Richettsiales (O)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU47416/97A 1996-10-01 1997-09-30 Compositions and methods for the prevention and diagnosis of human granulocytic ehrlichiosis Abandoned AU4741697A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2718096P 1996-10-01 1996-10-01
US60027180 1996-10-01
PCT/US1997/017675 WO1998014584A2 (en) 1996-10-01 1997-09-30 Compositions and methods for the prevention and diagnosis of human granulocytic ehrlichiosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU81548/01A Division AU8154801A (en) 1996-10-01 2001-10-23 Compositions and methods for the prevention and diagnosis of human granulocytic enrlichiosis

Publications (1)

Publication Number Publication Date
AU4741697A true AU4741697A (en) 1998-04-24

Family

ID=21836160

Family Applications (1)

Application Number Title Priority Date Filing Date
AU47416/97A Abandoned AU4741697A (en) 1996-10-01 1997-09-30 Compositions and methods for the prevention and diagnosis of human granulocytic ehrlichiosis

Country Status (5)

Country Link
EP (1) EP0932680A2 (ja)
JP (1) JP2001502528A (ja)
AU (1) AU4741697A (ja)
CA (1) CA2268013A1 (ja)
WO (1) WO1998014584A2 (ja)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673356B1 (en) 1997-03-21 2004-01-06 Corixa Corporation Compounds and methods for the diagnosis and treatment of ehrlichia infection
US6277381B1 (en) * 1997-03-21 2001-08-21 Corixa Corporation Compounds and methods for the diagnosis and treatment of Ehrlichia infection
US6231869B1 (en) 1997-03-21 2001-05-15 Corixa Corporation Compounds and methods for the diagnosis and treatment of ehrlichia infection
US6207169B1 (en) * 1997-03-21 2001-03-27 Corixa Corporation Compounds and methods for the diagnosis and treatment of Ehrlichia infection
EP2060631A3 (en) 1997-04-25 2009-07-15 Aquila Biopharmaceuticals, Inc. Characterization of granulocytic ehrlichia and methods of use
WO1999052370A1 (en) * 1998-04-09 1999-10-21 The Ohio State Research Foundation Nucleic acids encoding outer membrane protein of human granulocytic ehrlichiosis agent
US7807810B2 (en) 1999-04-08 2010-10-05 The Ohio State University Research Foundation Nucleic acids encoding the major outer membrane protein of the causative agent of human granulocytic ehrlichiosis and peptides encoded thereby
WO2008137881A2 (en) 2007-05-04 2008-11-13 The Ohio State University Research Foundation Ehrlichia ewingii proteins, nucleic acids, and methods of their use
WO2012135701A2 (en) 2011-03-31 2012-10-04 The Ohio State University Compositions and methods for the detection of anaplasma platys
WO2013113000A2 (en) 2012-01-26 2013-08-01 Luc Montagnier Detection of dna sequences as risk factors for hiv infection

Also Published As

Publication number Publication date
EP0932680A2 (en) 1999-08-04
CA2268013A1 (en) 1998-04-09
JP2001502528A (ja) 2001-02-27
WO1998014584A2 (en) 1998-04-09

Similar Documents

Publication Publication Date Title
US5747294A (en) Compositions and methods for the prevention and diagnosis of lyme disease
US6475492B1 (en) Peptides and assays for the diagnosis of lyme disease
KR102460165B1 (ko) Ospa의 돌연변이 단편 및 이와 관련된 방법 및 용도
US5656451A (en) OspE, OspF, and S1 polypeptides in borrelia burgdorferi
CZ280743B6 (cs) Imunogen proti lymské boreliose savců
CA2294701C (en) Surface antigens and proteins useful in compositions for the diagnosis and prevention of lyme disease
CA2077434C (en) Antigenic proteins of borrelia burgdorferi
AU4741697A (en) Compositions and methods for the prevention and diagnosis of human granulocytic ehrlichiosis
CA2112466A1 (en) Methods and compositions for diagnosing lyme disease
KR20130125771A (ko) 다가 키메라 ospc 백시노겐 및 진단 항원
CA2501939C (en) Novel immunogenic proteins of leptospira
US5780041A (en) 39-kilodalton antigen specific to Borrelia burgdorferi
ES2203704T3 (es) Proteinas de membrana de leptospira.
AU8154801A (en) Compositions and methods for the prevention and diagnosis of human granulocytic enrlichiosis
US6716591B1 (en) B. burgdorferi polypeptides
WO1997042325A1 (en) B. burgdorferi polypeptides expressed in vivo
CA2288433A1 (en) Compositions and methods for conferring tick immunity and preventing tick borne diseases
AU645078C (en) Antigenic proteins of (borrelia burgdorferi)
AU4392093A (en) Compositions useful in diagnosis and prophylaxis of lyme disease
CZ462199A3 (cs) Povrchové antigeny a proteiny použitelné v prostředcích pro diagnostiku a prevenci Lymské boreliosy

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted